David Maris - Wells Fargo


Last quote by David Maris

While the list encompasses a large number of branded products from many manufacturers, our review shows no company in our coverage universe is more exposed to this new FDA effort than Valeant. We note that some of these products are listed by Valeant as at risk of facing potential competition in the coming years. However, what is new is the FDA's focus on expediting competition on these products. We believe this is a risk factor for investors to be aware.feedback
share this quote
Jun 27 2017
We can learn a lot about a person if we know what types of things he or she talks about or comments on the most frequently. There are numerous topics with which David Maris is associated, including Allergan, Pfizer, and pricing. Most recently, David Maris has been quoted saying: “If generics [companies] are not already working on these, they will now. It is a shopping list. For the generic companies already working on these, the FDA news is great for them as it shows their filings, if early, will get priority.” in the article FDA aims to curb price gouging with list of off-patent medicines without generic competition. An other article where David Maris has been quoted is Drugmaker Mylan gets boost from unlikely source: coal.
Automatically powered by Storyzy
Take our quote verification challenge and find out !

David Maris quotes

Oct 10 2016

While some legislators may at first blush exclaim that the government has done its job in extracting some financial arrangement, we do not believe that this will be the end of the debate, as consumers will not see any of the money coming from the CMS/DOJ resolution.feedback

Sep 08 2016

Everyone understands that drug companies should make a little bit more each year; that their costs go up. Their people have to get paid more. Science costs more to do. But if we could limit maybe the outliers.feedback

Sep 08 2016

I don't think that having government run that process is really the right way, because it's a Trojan horse for price controls. Once they start controlling a little bit of price, then the temptation is to control all of price, and if you do that, you really get fewer drugs invented.feedback

Jun 10 2016

We believe that given the regulatory environment, these pricing actions could bring greater regulatory scrutiny and headline risk. Additionally, we wonder if aggressive price increases are being used to make EPS targets or to offset disappointing sales in other areas.feedback

Apr 05 2016

To us, whether Pfizer and Allergan stay committed will be known shortly–more important for many is if the deal breaks, where should Allergan trade?feedback

No quotes...
More David Maris quotes
|< <
> >|

Quotes by David Maris

Quote Verifier
Check if the quote you read on social networks is authentic
This webpage has been created by a robot: errors and absent quotes cannot be totally avoided

Quote :

Mistake :

Comments :